Jane Street
CVKD icon

Jane Street’s Cadrenal Therapeutics CVKD Stock Holding History

Jane Street’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.8K Buy
+13,721
New +$24.9K ﹤0.01% 11355

Other funds holding CVKD

HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Courier Capital
Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return
Vectors Research Management
Vectors Research Management New York $362M AUM 21.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Jane Street's CVKD Position: Q3 2026 in Review

Jane Street opened a new position in Cadrenal Therapeutics (CVKD) in Q3 2026: 13,721 shares worth $14.8K. The stake represents ﹤0.01% of the portfolio and ranks #11355 among its holdings.

21 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.

  • Jane Street held 13,721 shares of Cadrenal Therapeutics worth $14.8K as of Q3 2026.
  • Cadrenal Therapeutics was a new Jane Street position in Q3 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #11355 holding.
  • 21 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.